IN2014MN02164A - - Google Patents

Download PDF

Info

Publication number
IN2014MN02164A
IN2014MN02164A IN2164MUN2014A IN2014MN02164A IN 2014MN02164 A IN2014MN02164 A IN 2014MN02164A IN 2164MUN2014 A IN2164MUN2014 A IN 2164MUN2014A IN 2014MN02164 A IN2014MN02164 A IN 2014MN02164A
Authority
IN
India
Prior art keywords
activatable antibodies
egfr
moiety
antibody
variety
Prior art date
Application number
Inventor
Henry Bernard Lowman
Luc Roland Desnoyers
Shouchun Liu
James William West
Jason Gary Sagert
Olga Vasiljeva
Elizabeth Edna Mary MENENDEZ
Original Assignee
Cytomx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytomx Therapeutics Inc filed Critical Cytomx Therapeutics Inc
Publication of IN2014MN02164A publication Critical patent/IN2014MN02164A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Abstract

The invention relates generally to activatable antibodies that include a masking moiety (MM) a cleavable moiety (CM) and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR) and to methods of making and using these anti EGFR activatable antibodies in a variety of therapeutic diagnostic and prophylactic indications.
IN2164MUN2014 2012-04-27 2013-04-26 IN2014MN02164A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261639796P 2012-04-27 2012-04-27
US201261662204P 2012-06-20 2012-06-20
US201361749220P 2013-01-04 2013-01-04
US201361749529P 2013-01-07 2013-01-07
US201361763237P 2013-02-11 2013-02-11
PCT/US2013/038540 WO2013163631A2 (en) 2012-04-27 2013-04-26 Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof

Publications (1)

Publication Number Publication Date
IN2014MN02164A true IN2014MN02164A (en) 2015-08-28

Family

ID=49484042

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2164MUN2014 IN2014MN02164A (en) 2012-04-27 2013-04-26

Country Status (19)

Country Link
US (5) US9120853B2 (en)
EP (1) EP2841093A4 (en)
JP (2) JP2015516813A (en)
KR (1) KR102138743B1 (en)
CN (2) CN110078827A (en)
AU (2) AU2013251310B2 (en)
BR (1) BR112014026354A2 (en)
CA (1) CA2871458C (en)
CO (1) CO7160045A2 (en)
HK (1) HK1204581A1 (en)
IL (2) IL235331A0 (en)
IN (1) IN2014MN02164A (en)
MX (1) MX2014013041A (en)
PE (1) PE20150605A1 (en)
PH (1) PH12014502641A1 (en)
RU (1) RU2713121C2 (en)
SG (1) SG11201406943XA (en)
WO (1) WO2013163631A2 (en)
ZA (2) ZA201407715B (en)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2749339A1 (en) 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
CA3026701C (en) 2009-03-02 2023-04-18 Massachusetts Institute Of Technology Methods and products for in vivo enzyme profiling
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
MX2014013041A (en) 2012-04-27 2015-03-19 Cytomx Therapeutics Inc Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof.
CN112162094A (en) 2013-01-04 2021-01-01 西托姆克斯治疗公司 Compositions and methods for detecting protease activity in biological systems
AU2014240012A1 (en) * 2013-03-15 2015-09-24 Abbvie Inc. Antibody drug conjugate (ADC) purification
CA2913051C (en) 2013-05-28 2023-09-05 Dcb-Usa Llc Antibody locker for the inactivation of protein drug
JP6462673B2 (en) * 2013-07-05 2019-01-30 フォーメーション バイオロジックス インコーポレイテッド EGFR antibody conjugate
EP3406633B1 (en) * 2013-07-25 2022-03-02 Cytomx Therapeutics Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
US20150087810A1 (en) 2013-09-25 2015-03-26 Cytomx Therapeutics, Inc. Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use Thereof
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2015089283A1 (en) * 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
BR122023022856A2 (en) * 2014-01-31 2023-12-12 Cytomx Therapeutics, Inc. ISOLATED POLYPEPTIDE COMPRISING MATRIPTASE AND PLASMINOGEN ACTIVATOR U SUBSTRATES AND OTHER CLEAABLE MOTIONS, PHARMACEUTICAL COMPOSITION COMPRISING SAID POLYPEPTIDE, AS WELL AS METHODS FOR PRODUCING AND MANUFACTURING AN ISOLATED POLYPEPTIDE COMPRISING A CLEAABLE MOTION AND USE AND THERAPEUTICLY EFFECTIVE AMOUNT OF SAID PHARMACEUTICAL COMPOSITION
KR102307278B1 (en) * 2014-04-29 2021-09-30 노파르티스 아게 Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest
WO2016014974A2 (en) * 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
CN104910275A (en) * 2014-12-04 2015-09-16 上海张江生物技术有限公司 Novel anti-epidermal growth factor receptor antibody, preparation method and application thereof
MA41374A (en) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc MATRIX METALLOPROTEASE CLIVABLE AND SERINE PROTEASE CLIVABLE SUBSTRATES AND METHODS OF USE THEREOF
IL292449B2 (en) * 2015-03-13 2024-02-01 Cytomx Therapeutics Inc Nucleic acids encoding anti-pdl1 antibodie and methods of producing same
EP3292151A1 (en) * 2015-05-04 2018-03-14 Cytomx Therapeutics Inc. Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof
TWI726879B (en) 2015-05-04 2021-05-11 美商Ｃｙｔｏｍｘ生物製藥公司 Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof
EP3292150B1 (en) 2015-05-04 2020-02-05 Cytomx Therapeutics Inc. Activatable anti-cd166 antibodies, and methods of use thereof
CN108431018A (en) * 2015-06-12 2018-08-21 王天欣 The method of protein modification in medicinal application
JP2018526972A (en) 2015-06-16 2018-09-20 ジェネンテック， インコーポレイテッド Anti-CD3 antibody and method of use
CA2986604A1 (en) * 2015-06-26 2016-12-29 University Of Southern California Masking chimeric antigen receptor t cells for tumor-specific activation
US11466093B2 (en) 2015-07-27 2022-10-11 The General Hospital Corporation Antibody derivatives with conditionally enabled effector function
CN108135968A (en) 2015-08-28 2018-06-08 阿穆尼克斯运营公司 Chimeric polyeptides assembly and its preparation and application
CN105399830B (en) * 2015-09-08 2019-11-19 北京天广实生物技术股份有限公司 Anti- EGFR Humanized monoclonal antibodies, preparation method and the usage
CN106519037B (en) * 2015-09-11 2019-07-23 科济生物医药（上海）有限公司 Activable Chimerical receptor
EA039736B1 (en) * 2015-09-15 2022-03-04 Сайтомкс Терапьютикс, Инк. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
JP7115982B2 (en) 2015-10-30 2022-08-09 アレタ・バイオセラピューティクス・インコーポレイテッド Compositions and methods for treating cancer
WO2017075533A1 (en) 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions and methods for tumor transduction
WO2017087789A1 (en) 2015-11-19 2017-05-26 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
WO2017143094A1 (en) * 2016-02-16 2017-08-24 Dana-Farber Cancer Institute, Inc. Immunotherapy compositions and methods
WO2017177115A1 (en) 2016-04-08 2017-10-12 Massachusetts Institute Of Technology Methods to specifically profile protease activity at lymph nodes
CA3022928A1 (en) 2016-05-05 2017-11-09 Massachusetts Institute Of Technology Methods and uses for remotely triggered protease activity measurements
CN110072890B (en) * 2016-11-03 2022-11-29 百时美施贵宝公司 Activatable anti-CTLA-4 antibodies and uses thereof
AU2017371225A1 (en) 2016-12-09 2019-05-16 Seagen Inc. Bivalent antibodies masked by coiled coils
EP3592775A1 (en) * 2017-03-09 2020-01-15 CytomX Therapeutics, Inc. Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof
AU2018248327A1 (en) 2017-04-07 2019-10-17 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
KR20200016899A (en) 2017-06-01 2020-02-17 싸이톰스 테라퓨틱스, 인크. Activatable anti-PDL1 antibody, and methods of using the same
US11220544B2 (en) 2017-07-14 2022-01-11 Cytomx Therapeutics, Inc. Anti-CD166 antibodies and uses thereof
CN110998329A (en) * 2017-07-20 2020-04-10 西托姆克斯治疗公司 Method for qualitative and/or quantitative analysis of the properties of activatable antibodies and uses thereof
JP2020531430A (en) 2017-08-16 2020-11-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Anti-CTLA4 probody therapy targeting antibodies
CN111356700A (en) 2017-09-08 2020-06-30 马弗里克治疗公司 Constrained conditionally activated binding proteins
TW201927816A (en) 2017-10-14 2019-07-16 美商Ｃｙｔｏｍｘ生物製藥公司 Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
WO2019113385A1 (en) * 2017-12-07 2019-06-13 Janux Therapeutics, Inc. Modified t cell receptors
MX2020006297A (en) 2017-12-15 2020-12-07 Aleta Biotherapeutics Inc Cd19 variants.
AU2019218959A1 (en) 2018-02-08 2020-09-03 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
WO2019173332A1 (en) 2018-03-05 2019-09-12 Massachusetts Institute Of Technology Inhalable nanosensors with volatile reporters and uses thereof
EP3769309A1 (en) 2018-03-20 2021-01-27 Cytomx Therapeutics Inc. Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects
CA3100007A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
US20210269530A1 (en) * 2018-05-14 2021-09-02 Harpoon Therapeutics, Inc. Conditionally activated binding protein comprising a sterically occluded target binding domain
CA3100005A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
US11153281B2 (en) 2018-12-06 2021-10-19 Bank Of America Corporation Deploying and utilizing a dynamic data stenciling system with a smart linking engine
US11835522B2 (en) 2019-01-17 2023-12-05 Massachusetts Institute Of Technology Sensors for detecting and imaging of cancer metastasis
CN114390938A (en) 2019-03-05 2022-04-22 武田药品工业有限公司 Constrained conditionally activated binding proteins
BR112021022666A2 (en) 2019-05-14 2022-03-29 Werewolf Therapeutics Inc Separation fractions and their methods and use
CN114423499A (en) * 2019-06-06 2022-04-29 佳努克斯治疗公司 Compositions and methods related to tumor-activated T cell adaptors
WO2020251878A1 (en) 2019-06-11 2020-12-17 Bristol-Myers Squibb Company Anti-ctla4 antibody prodruggable (probody) at a cdr position
WO2021061867A1 (en) * 2019-09-23 2021-04-01 Cytomx Therapeutics, Inc. Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof
PE20221511A1 (en) 2019-12-13 2022-10-04 Genentech Inc ANTI-LY6G6D ANTIBODIES AND METHODS OF USE
CN114945597A (en) * 2020-01-17 2022-08-26 艾提欧生物疗法有限公司 Pre-antibodies to reduce off-target toxicity
WO2021146590A2 (en) * 2020-01-17 2021-07-22 Aetio Biotherapy, Inc. Pro-antibody that reduces off-target toxicity
EP4132656A1 (en) 2020-04-09 2023-02-15 CytomX Therapeutics, Inc. Compositions containing activatable antibodies
US11512113B2 (en) * 2020-08-11 2022-11-29 Janux Therapeutics, Inc. Cleavable linker compositions and methods
KR20230135575A (en) 2020-12-09 2023-09-25 재눅스 테라퓨틱스 인크. Compositions and methods related to tumor-activating antibodies targeting PSMA and effector cell antigens
TW202311289A (en) * 2021-05-12 2023-03-16 美商詹努克斯治療有限公司 Compositions and methods related to tumor activated antibodies targeting egfr and effector cell antigens
WO2023064927A1 (en) 2021-10-15 2023-04-20 Cytomx Therapeutics, Inc. Activatable polypeptide complex
US20230174995A1 (en) 2021-10-15 2023-06-08 Cytomx Therapeutics, Inc. Activatable polypeptide complex
WO2023064955A1 (en) 2021-10-15 2023-04-20 Cytomx Therapeutics, Inc. Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
WO2023148388A1 (en) * 2022-02-04 2023-08-10 Zytox Therapeutics Ab Fusion protein comprising an egfr-binding domain and a masking domain
WO2024046396A1 (en) * 2022-08-31 2024-03-07 洪明奇 Anti-meegfr antibody, antigen-binding fragment thereof, and use thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE3788058T2 (en) 1986-08-28 1994-04-21 Teijin Ltd CELL TOXIC ANTIBODY COMPLEX AND METHOD FOR THE PRODUCTION THEREOF.
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
DK0669836T3 (en) 1992-11-13 1996-10-14 Idec Pharma Corp Therapeutic use of chimeric and radiolabeled antibodies and human B lymphocyte restricted differentiation antigen for the treatment of B cell lymphoma
AU1707497A (en) 1996-01-23 1997-08-20 Rigel Pharmaceuticals, Inc. Methods for screening for transdominant intracellular effector peptides and rna molecules
GB9603507D0 (en) 1996-02-20 1996-04-17 Isis Innovation Antibody variants
TW505653B (en) 1996-02-26 2002-10-11 Meiji Seika Co Triterpene derivatives possessing an effect of treating liver diseases and pharmacentical compositions containing the same
JP2001505872A (en) 1996-09-09 2001-05-08 ジーランド ファーマシューティカルズ アクティーゼルスカブ Peptide prodrug containing α-hydroxy acid linker
JP2003530839A (en) * 2000-04-12 2003-10-21 プリンシピア ファーマスーティカル コーポレイション Albumin fusion protein
EP1286700A2 (en) * 2000-06-01 2003-03-05 Universite Catholique De Louvain Tumor activated prodrug compounds
ES2368387T5 (en) 2000-10-09 2019-03-07 Cytomx Therapeutics Inc Therapeutic and tolerance-inducing antibodies
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US6989452B2 (en) * 2001-05-31 2006-01-24 Medarex, Inc. Disulfide prodrugs and linkers and stabilizers useful therefor
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
AU2003265866A1 (en) 2002-09-03 2004-03-29 Vit Lauermann Targeted release
US20040111757A1 (en) * 2002-12-05 2004-06-10 Dongxiao Zhang Multiplex system for production and screening of monoclonal antibodies
US8088387B2 (en) * 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
AR048098A1 (en) * 2004-03-15 2006-03-29 Wyeth Corp CALIQUEAMYCIN CONJUGATES
CN102875681A (en) * 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 Anti-alpha v beta 6 antibodies and uses thereof
CA2620886C (en) 2005-08-31 2017-03-14 The Regents Of The University Of California Cellular libraries of peptide sequences (clips) and methods of using the same
JP2009529522A (en) * 2006-03-10 2009-08-20 ディアト Anticancer drug conjugated to antibody via enzyme-cleavable linker
KR20140085544A (en) 2006-05-30 2014-07-07 제넨테크, 인크. Antibodies and immunoconjugates and uses therefor
CA2654000A1 (en) 2006-06-06 2008-05-22 Genentech, Inc. Anti-dll4 antibodies and methods using same
US8450068B2 (en) * 2007-02-16 2013-05-28 University Of Virginia Patent Foundation IgE antibodies to chimeric or humanized IgG therapeutic monoclonal antibodies as a screening test for anaphylaxis
EP2487190A3 (en) 2007-07-13 2012-11-14 Bac Ip B.V. Single-domain antigen-binding proteins that bind mammalian IgG
US8293685B2 (en) 2007-07-26 2012-10-23 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
CA3128656A1 (en) 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
BRPI0819693A2 (en) * 2007-11-30 2020-08-18 Glaxo Group Limited CONSTRUCTION OF ANTIGEN BINDING, METHOD FOR TREATING A PATIENT SUFFERING FROM CANCER OR AN INFLAMMATORY DISEASE, POLYNUCLEOTIDE SEQUENCE, POLYNUCLEOTIDE, HOSTED CELL, TRANSFORMED, EFFECTIVENESS, HUMAN RESOURCE
CA2720124C (en) 2008-05-13 2015-07-21 Genentech, Inc. Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry
US20110178279A1 (en) 2009-08-03 2011-07-21 Williams John C Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies
US8895702B2 (en) * 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
WO2010077643A1 (en) 2008-12-08 2010-07-08 Tegopharm Corporation Masking ligands for reversible inhibition of multivalent compounds
CA2749339A1 (en) 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
CA2761310C (en) 2009-05-07 2017-02-28 Charles S. Craik Antibodies and methods of use thereof
PL2542590T5 (en) 2010-03-05 2020-08-10 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
US9193791B2 (en) 2010-08-03 2015-11-24 City Of Hope Development of masked therapeutic antibodies to limit off-target effects
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
CA2849705A1 (en) 2011-09-23 2013-03-28 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Modified albumin-binding domains and uses thereof to improve pharmacokinetics
MX2014013041A (en) 2012-04-27 2015-03-19 Cytomx Therapeutics Inc Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof.
BR112015030514A2 (en) 2013-06-04 2017-08-29 Cytomx Therapeutics Inc COMPOSITIONS AND METHODS FOR CONJUGATION OF ACTIVABABLE ANTIBODIES
EP3406633B1 (en) 2013-07-25 2022-03-02 Cytomx Therapeutics Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2015089283A1 (en) 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof

Also Published As

Publication number Publication date
CO7160045A2 (en) 2015-01-15
AU2013251310A1 (en) 2014-11-06
CA2871458C (en) 2020-06-23
US10709799B2 (en) 2020-07-14
AU2018203262A1 (en) 2018-05-31
WO2013163631A2 (en) 2013-10-31
SG11201406943XA (en) 2014-12-30
US9545442B2 (en) 2017-01-17
PE20150605A1 (en) 2015-05-28
US9889211B2 (en) 2018-02-13
ZA201407715B (en) 2015-12-23
HK1204581A1 (en) 2015-11-27
ZA201507859B (en) 2017-08-30
JP2015516813A (en) 2015-06-18
CA2871458A1 (en) 2013-10-31
CN110078827A (en) 2019-08-02
RU2014147684A (en) 2016-06-20
PH12014502641B1 (en) 2015-02-02
CN104540518A (en) 2015-04-22
US20160193332A1 (en) 2016-07-07
IL265788A (en) 2019-06-30
EP2841093A4 (en) 2016-04-06
EP2841093A2 (en) 2015-03-04
US20210023243A1 (en) 2021-01-28
MX2014013041A (en) 2015-03-19
KR20150035538A (en) 2015-04-06
US20180333507A1 (en) 2018-11-22
AU2013251310B2 (en) 2018-02-15
RU2713121C2 (en) 2020-02-03
PH12014502641A1 (en) 2015-02-02
US11890354B2 (en) 2024-02-06
US20130315906A1 (en) 2013-11-28
US9120853B2 (en) 2015-09-01
BR112014026354A2 (en) 2017-06-27
WO2013163631A3 (en) 2014-01-09
US20170196996A1 (en) 2017-07-13
KR102138743B1 (en) 2020-07-29
JP2019108331A (en) 2019-07-04
IL235331A0 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
IN2014MN02164A (en)
WO2015066279A3 (en) Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2014052462A3 (en) Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
PH12015500125A1 (en) Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
EP2566890A4 (en) Anti-pai-1 antibodies and methods of use thereof
TN2015000396A1 (en) Antibody drug conjugates
CL2015000582A1 (en) Anti-mcam antibodies and associated methods of use
AU2012335543A8 (en) HER3 antibodies and uses thereof
PH12014501427A1 (en) Anti-php-tau antibodies and their uses
EP4249065A3 (en) Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
NZ629913A (en) Anti-ox40 antibodies and methods of using the same
EP3461847A8 (en) Humanized antibodies to liv-1 and use of same to treat cancer
TR201905909T4 (en) Combinations of anti-4-1bb antibodies and adcc inducing antibodies for cancer therapy.
PE20151926A1 (en) ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE
MX2012007676A (en) Antibody formulation.
MX352738B (en) Cytotoxic peptides and antibody drug conjugates thereof.
MX2013011353A (en) Antibody-drug conjugates.
NZ601588A (en) Methods for treating breast cancer
MX2013011706A (en) Novel egfr binding proteins.
BRPI1014544B8 (en) isolated fully human monoclonal anti-il-17f antibody and pharmaceutical composition comprising the same
MX346500B (en) Methods and compositions for neural disease immunotherapy.
NZ611785A (en) Anti-notch1 antibodies
TR201903312T4 (en) Methods to reduce asthma exacerbation rates using benralizumab.
NZ603191A (en) Methods for the treatment of il-1b related conditions
MX2013002960A (en) Antibody compositions and methods of use.